These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36428459)

  • 1. Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem.
    Sertić Z; Lucijanić M; Bašić-Kinda S; Serventi Seiwerth R; Periša V; Sertić D; Coha B; Pulanić D; Perić Z; Desnica L; Mikulić M; Vodanović M; Radman-Livaja I; Šegulja D; Rogić D; Valković T; Aurer I; Duraković N
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
    Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
    Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study.
    Gueguen M; Khatchatourian L; Lohéac C; Dorval I; Mercier M; Le Calloch R; Mahé K; Rizcallah MJ; Hutin P; Fangous MS; Saidani N; Le Clech L
    Infect Dis Now; 2022 Aug; 52(5):280-285. PubMed ID: 35667558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.
    Giuliano AR; Lancet JE; Pilon-Thomas S; Dong N; Jain AG; Tan E; Ball S; Tworoger SS; Siegel EM; Whiting J; Mo Q; Cubitt CL; Dukes CW; Hensel JA; Keenan RJ; Hwu P
    JAMA Oncol; 2022 May; 8(5):748-754. PubMed ID: 35266953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
    Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
    Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study.
    Diamantopoulos PT; Stafylidis C; Vlachopoulou D; Kontandreopoulou CN; Giannakopoulou N; Vardaka M; Mpouhla A; Mastrogianni E; Variami E; Galanopoulos A; Pappa V; Psichogiou M; Hatzakis A; Viniou NA
    Ther Adv Hematol; 2022; 13():20406207221090150. PubMed ID: 35646300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center.
    Prasad N; Bansal SB; Yadav B; Manhas N; Yadav D; Gautam S; Kushwaha R; Singh A; Bhadauria D; Yachha M; Behera MR; Kaul A
    Front Immunol; 2022; 13():911738. PubMed ID: 35844596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study.
    Doukas PG; St Pierre F; Karmali R; Mi X; Boyer J; Nieves M; Ison MG; Winter JN; Gordon LI; Ma S
    Oncologist; 2023 Oct; 28(10):e930-e941. PubMed ID: 37141401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination for SARS-CoV-2 in Hematological Patients.
    Riccardi N; Falcone M; Yahav D
    Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.
    Diefenbach C; Caro J; Koide A; Grossbard M; Goldberg JD; Raphael B; Hymes K; Moskovits T; Kreditor M; Kaminetzky D; Fleur-Lominy SS; Choi J; Thannickal SA; Stapleford KA; Koide S
    medRxiv; 2021 Jun; ():. PubMed ID: 34100025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
    Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
    J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
    Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
    ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection.
    La Verde N; Riva A; Cona MS; Gabrieli A; Cattaneo M; Fasola C; Lipari G; De Stradis C; Favorito V; Lombardi Stocchetti B; Chizzoniti D; Covizzi A; Rulli E; Galli F; Ruggieri L; Gambaro A; Ferrario S; Dalu D; Tarkowski MS
    Int J Cancer; 2023 Feb; 152(4):661-671. PubMed ID: 36056571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study.
    Terpos E; Gavriatopoulou M; Fotiou D; Giatra C; Asimakopoulos I; Dimou M; Sklirou AD; Ntanasis-Stathopoulos I; Darmani I; Briasoulis A; Kastritis E; Angelopoulou M; Baltadakis I; Panayiotidis P; Trougakos IP; Vassilakopoulos TP; Pagoni M; Dimopoulos MA
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
    Bagacean C; Letestu R; Al-Nawakil C; Brichler S; Lévy V; Sritharan N; Delmer A; Dartigeas C; Leblond V; Roos-Weil D; Tomowiak C; Merabet F; Béné MC; Clavert A; Chaoui D; Genet P; Guieze R; Laribi K; Drénou B; Willems L; Puppinck C; Legendre H; Troussard X; Malartre S; Cymbalista F; Michallet AS
    Blood Adv; 2022 Jan; 6(1):207-211. PubMed ID: 34844264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.